HISOAR(SZ:002099) Xin Lang Cai Jing·2026-01-07 05:30Group 1 - The core viewpoint of the news is that Haixiang Pharmaceutical experienced a stock price increase of 5.07%, reaching 6.84 CNY per share, with a trading volume of 194 million CNY and a turnover rate of 1.84%, resulting in a total market capitalization of 11.072 billion CNY [1] - Haixiang Pharmaceutical, established on May 7, 1998, and listed on December 26, 2006, is located in Taizhou, Zhejiang Province. The company specializes in the production and sales of fine chemicals (intermediates for active pharmaceutical ingredients) and specialty active pharmaceutical ingredients, including antibiotics, antiviral drugs, cardiovascular drugs, antiparasitics, and hypoglycemic agents [1] - The revenue composition of Haixiang Pharmaceutical includes 56.07% from active pharmaceutical ingredients and intermediates, 33.09% from dyes and dye intermediates, 9.34% from contract customization services, 1.02% from other sources, and 0.49% from formulations [1] Group 2 - Among the top circulating shareholders of Haixiang Pharmaceutical, a fund under Southern Fund holds a significant position. The Southern CSI 1000 ETF (512100) reduced its holdings by 170,300 shares in the third quarter, now holding 10.3583 million shares, which accounts for 0.64% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. It has achieved a year-to-date return of 3.56%, ranking 2808 out of 5488 in its category, and a one-year return of 42.19%, ranking 1726 out of 4192 [2]